Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma

被引:5
|
作者
Anthony, Casey L. [1 ]
Bavinger, J. Clay [1 ]
Shantha, Jessica G. [1 ]
O'Keefe, Ghazala D. [1 ]
Pearce, William A. [1 ]
Voloschin, Alfredo [2 ]
Grossniklaus, Hans E. [1 ]
Yeh, Steven [1 ,3 ]
机构
[1] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Med Hematol & Oncol, Atlanta, GA USA
[3] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Dept Ophthalmol, 3902 Leavenworth St, Omaha, NE 68106 USA
基金
美国国家卫生研究院;
关键词
Primary vitreoretinal lymphoma; Primary intraocular lymphoma; Primary central nervous system lymphoma; Methotrexate; Intravitreal; PCNSL; PVRL; PIOL; Uveitis; Masquerade syndrome; PRIMARY INTRAOCULAR LYMPHOMA; NERVOUS-SYSTEM LYMPHOMA;
D O I
10.1186/s40942-021-00346-0
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To describe the visual acuity and anatomic outcomes of intravitreal methotrexate (MTX) for the treatment of primary vitreoretinal lymphoma (PVRL). Methods Single-center retrospective case series of patients with a diagnosis of PVRL treated with intravitreal MTX. Patient records were reviewed for demographic information, ocular exam findings, and treatment regimens including number of MTX injections. Clinical outcomes recorded included visual acuity (VA), time to partial (PR) or complete response (CR), disease-free survival, time to relapse, and any CNS progression. Results Ten eyes of 7 patients (4 male, 6 female) were reviewed. The mean age +/- standard deviation (SD) was 70 +/- 12 years. Five patients had prior or concomitant diagnosis of primary CNS lymphoma with a history of systemic chemotherapy including MTX. Three eyes (30%) exhibited isolated vitreous involvement, four (40%) had subretinal lesions, and three (30%) presented with both vitreous and subretinal disease. Mean initial logMAR VA was 0.38 +/- 0.52 (Snellen visual equivalent 20/50), while mean final logMAR VA +/- SD was 0.34 +/- 0.27 (Snellen visual equivalent 20/40) with a mean follow-up time of 26 months (Range, 3-49 months). Patients received an average of 6 intravitreal MTX injections (Range 1-10) over the course of treatment. Two patients received concomitant systemic chemotherapy. Mean time to either PR or CR was 57 days, and 6 eyes (60%) exhibited regression with no relapse after local treatment. For the 4 eyes that eventually relapsed, the mean time +/- SD to first relapse was 193 days +/- 155 days, and one eye experienced a second relapse. Two of 3 patients with subretinal disease showed complete regression with extended follow-up of 1 and 4 years following treatment with less than 3 doses of intravitreal MTX. One patient with PVRL developed CNS lymphoma during the study period. VA remained stable overall between the initial treatment visit, 3, 6, and 12-months (P > 0.05 for paired comparisons of VA over time). Conclusions Intravitreal methotrexate was well-tolerated and led to local disease response in the majority of patients at approximately 2 months after initiation of treatment of intraocular lymphoma. Further studies on the efficacy of intravitreal treatment alone versus combined systemic and intravitreal treatment are warranted.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Intravitreal melphalan for vitreoretinal lymphoma
    Lim, Li-Anne
    Dalvin, Lauren
    Ancona-Lezama, David
    Chang, Michael
    Mashayekhi, Arman
    Shields, Carol
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 : 48 - 49
  • [22] Intravitreal melphalan for vitreoretinal lymphoma
    Lim, Li-Anne S.
    Dalvin, Lauren A.
    Ancona-Lezama, David
    Chang, Michael
    Mashayekhi, Arman
    Shields, Carol L.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [23] Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients
    Zhou, Xian
    Zhou, Xianjin
    Shi, Huimin
    Lai, Jie
    Wang, Qingping
    Li, Yi
    Chen, Kun
    Li, Qingjian
    Zhou, Qiang
    Cao, Xia
    Chen, Bobin
    Xiao, Jianjiang
    BMC OPHTHALMOLOGY, 2020, 20 (01)
  • [24] Intravitreal methotrexate resistance in a patient with primary Intraocular lymphoma
    Sen, H. Nida
    Chan, Chi-Chao
    Byrnes, Gordon
    Fariss, Robert N.
    Nussenblatt, Robert B.
    Buggage, Ronald R.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2008, 16 (1-2) : 29 - 33
  • [25] Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients
    Xian Zhou
    Xianjin Zhou
    Huimin Shi
    Jie Lai
    Qingping Wang
    Yi Li
    Kun Chen
    Qingjian Li
    Qiang Zhou
    Xia Cao
    Bobin Chen
    Jianjiang Xiao
    BMC Ophthalmology, 20
  • [26] Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection
    Wei-Li Ma
    Hsin-An Hou
    Ya-Jui Hsu
    Yin-Kai Chen
    Jih-Luh Tang
    Woei Tsay
    Po-Ting Yeh
    Chung-May Yang
    Chang-Ping Lin
    Hwei-Fang Tien
    Annals of Hematology, 2016, 95 : 593 - 601
  • [27] Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate
    Gu, Junxiang
    Jiang, Tingting
    Liu, Shixue
    Chen, Xiuju
    Wang, Zhujian
    Zhang, Peijun
    Wang, Ling
    Jiang, Rui
    Huang, Xin
    Xu, Gezhi
    Chang, Qing
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 251 : 189 - 196
  • [28] Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection
    Ma, Wei-Li
    Hou, Hsin-An
    Hsu, Ya-Jui
    Chen, Yin-Kai
    Tang, Jih-Luh
    Tsay, Woei
    Yeh, Po-Ting
    Yang, Chung-May
    Lin, Chang-Ping
    Tien, Hwei-Fang
    ANNALS OF HEMATOLOGY, 2016, 95 (04) : 593 - 601
  • [29] Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma
    Hashida, Noriyasu
    Ohguro, Nobuyuki
    Nishida, Kohji
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2012, 1 (03):
  • [30] Clinical outcomes of intravitreal methotrexate injection protocol with a reduced initial frequency for intraocular lymphoma
    Hsu, Chiung-Ju
    Hou, Hsin-An
    Lin, Chang-Ping
    Lee, Yi-Jui
    Hsu, Wen-Fang
    Yeh, Po-Ting
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (01) : 416 - 424